Crosslinking Level | Gel Texture | Concentration | Needles | Injection Depth | Availability | |
---|---|---|---|---|---|---|
e.p.t.q. S100 | ● ○ ○ |
![]() |
HA 24 mg/ml | 27 G | Superficial / Mid Dermis | Available |
e.p.t.q. S100 lidocaine | ● ○ ○ |
![]() |
HA 24 mg/ml Lidocaine 0,3% | 27 G | Superficial / Mid Dermis | Available in Q1 2020 |
e.p.t.q. S300 | ● ● ○ |
![]() |
HA 24 mg/ml | 27 G | Mid / Deep Dermis | Available |
e.p.t.q. S300 lidocaine | ● ● ○ |
![]() |
HA 24 mg/ml Lidocaine 0,3% | 27 G | Mid / Deep Dermis | Available in Q1 2020 |
e.p.t.q. S500 | ● ● ● |
![]() |
HA 24 mg/ml | 27 G | Subcutaneous / Supraperiosteal areas | Available |
e.p.t.q. S500 lidocaine | ● ● ● |
![]() |
HA 24 mg/ml Lidocaine 0,3% | 27 G | Subcutaneous / Supraperiosteal areas | Available in Q1 2020 |